Skip to main content

OPRX

Stock
Health Care
Health Information Services

Performance overview

OPRX Price
Price Chart

Forward-looking statistics

Beta
0.89
Risk
78.92%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Company info

SectorHealth Care
IndustryHealth Information Services
Employees121
Market cap$203.2M

Fundamentals

Enterprise value$265.9M
Revenue$94.4M
Revenue per employee—
Profit margin-16.33%
Debt to equity28.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.84
Dividend per share—
Revenue per share$5.14
Avg trading volume (30 day)$4M
Avg trading volume (10 day)$3M
Put-call ratio—

Macro factor sensitivity

Growth+1.3
Credit+4.8
Liquidity-0.2
Inflation-5.2
Commodities+0.4
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio27.41
Price to sales2.63
P/E Ratio27.41
Enterprise Value to Revenue2.82
Price to book2.14

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?

OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.

Zacks Investment Research (July 11, 2025)
OptimizeRx Clocks Double-Digit Revenue Growth In Q4, Forecasts Sales Of At Least $100 Million

OPTIMIZERx Corp. OPRX, a health care technology firm, reported on Wednesday fourth-quarter sales of $32.32 million, up 14% year-over-year, beating the consensus of $30.36 million.

Benzinga (March 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free